Navigation Links
HeartWare to Present at the UBS Global Life Sciences Conference
Date:9/14/2011

FRAMINGHAM, Mass. and SYDNEY, Sept. 14, 2011 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the UBS Global Life Sciences Conference at 10:30 a.m. ET on Wednesday, September 21, 2011.  The conference is being held September 19-21, 2011 at the Grand Hyatt in New York City.

A live webcast of the Company's presentation at the conference will be available via a link provided at www.heartware.com.  A replay of the webcast will be available at the site after the presentation.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure.  The HeartWare® Ventricular Assist System features the HVAD® Pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices.  HeartWare has received CE Marking for the HeartWare System in the European Union and TGA approval in Australia.  The device is currently the subject of United States clinical trials for two indications: bridge-to-transplant and destination therapy.  For additional information, please visit www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

HEARTWARE, HVAD, MVAD and HeartWare logos are registered trademarks of HeartWare, Inc.

For further information:
Christopher Taylor
HeartWare International, Inc.

Email: ctaylor@heartwareinc.com
Phone: +1 508 739 0864


'/>"/>
SOURCE HeartWare International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. HeartWare Completes GLP Studies of Next Generation MVAD® Pump; Data Presented Today at ISRBP Congress
2. HeartWare to Report 2010 Fourth Quarter and Year-End Financial Results
3. HeartWare to Present at the 22nd Annual Piper Jaffray Health Care Conference
4. HeartWare International, Inc. Temporary Suspension of Trading
5. U.S. Federal Trade Commission to Challenge Thoratecs Proposed Acquisition of HeartWare International
6. Sangamo BioSciences Announces Presentation at the 2011 UBS Global Life Sciences Conference
7. Tengion to Present at UBS Global Life Sciences Conference
8. Healthpoint Biotherapeutics to Present at UBS Global Life Sciences Conference
9. Saladax Biomedical, Inc. to Present at the Annual UBS Global Life Sciences Conference in New York City
10. Metabolic Solutions Development Company Presents New Brown Fat Research at the European Association for the Study of Diabetes
11. Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... April 27, 2017 , ... Proscia Inc., ... digital pathology technology has the potential to eliminate subjectivity in the detection and ... Netherlands as part of the 2017 ISBI CAMELYON Digital Pathology Challenge, ...
(Date:4/27/2017)... , ... April 27, 2017 , ... ... explaining why mass flow controllers based on capillary thermal mass flow technology provide ... mass flow control applications. Over 80% of all industrial processes—such as those ...
(Date:4/27/2017)... 27, 2017  Kinexum, a distinguished resource for research, ... the appointment of Thomas C. Seoh as ... M.D., Kinexum founder, who becomes Executive Chairman and will ... clients. Thomas Seoh commented, "I ... mission and lead the firm,s remarkable team of life ...
(Date:4/26/2017)... ... 26, 2017 , ... Baltimore bio tech firm, PathSensors, Inc., ... solution at the National Postal Forum 2017 in Baltimore, Maryland, May 21st through ... easy to use and low cost threat detection solution for government and commercial ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
Breaking Biology News(10 mins):